Our follow-up study investigated the scientific premise of progressive Aβ accumulation in 6-month-old 3xTg-AD mice expressing elevated PLD1 [42], and more importantly, established PLD1 inhibition as a viable therapeutic target in mediating cognitive decline against Aβ. This evidence concerns the gene PLD1 and Alzheimer disease.